Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting

American Journal of Cardiovascular Drugs

Volumn 4, Issue 1, 2004, Pages 31-41

  Granada, Juan F ^a   Kleiman, Neal S ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FUROSEMIDE; HEPARIN; PLACEBO; SNAKE VENOM; THROMBOCYTE RECEPTOR; TIROFIBAN;

BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG ISOLATION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTIVE SURGERY; EXPERIMENTAL DESIGN; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; CLINICAL TRIALS; CORONARY DISEASE; CORONARY THROMBOSIS; HUMANS; PEPTIDES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; SURGICAL PROCEDURES, ELECTIVE; SYNDROME; TREATMENT OUTCOME;

EID: 1342325727     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404010-00004     Document Type: Review

References (50)

1. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992; 326: 242-50
2. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet 1996; 348 Suppl. 1: s7-s10
3. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9
4. Plow EF, Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors and the peptides that inhibit these interactions. Biochem Pharmacol 1987; 36: 4035-40
5. Andrieux A, Hudry-Clergeon G, Ryckewaert J-J, et al. Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GP IIb/IIIa. J Biol Chem 1989; 264: 9258-65
6. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38
7. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35
8. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998; 98: 2629-35
9. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103-15
10. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-73
11. Scarborough RM, Hsu MA, Teng W, et al. C68-22, a novel glycoprotein (GP) IIb-IIIa specific platelet aggregation inhibitor designed from the structure of barbourin (abstract). Arterioscler Thromb 1991; 11: 1591a
12. Plow EF, Ginsberg MH. Cellular adhesion: GP IIb/IIIa as a prototype adhesion receptor. Prog Hemost Thromb 1989; 9: 117-56
13. Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2002; 15 (1): 45-60
14. Alton KB, Kosoglou T, Baker S, et al. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998; 20 (2): 307-23
15. Integrilin® (eptifibatide) prescribing information. South San Francisco (CA): Millenium Pharmaceuticals, Inc., 2002 Aug
16. Bates ER, McGillem MJ, Mickelson JK, et al. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991; 84: 2463-9
17. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-7
18. Coller BS, Folts JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: correlation with bleeding time, platelet aggregation and blockade of GP IIb/IIIa receptors. Circulation 1989; 80: 1766-74
19. Harrington RA, Kleiman NS, Granger CB, et al. Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J 1998; 136: S43-50
20. White MM, Jennings LK. Platelet protocols. San Diego (CA): Academic Press, 1999
21. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-7
22. Tardiff BE, Jennings LK, Harrington RA, et al. for PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001; 104: 399-405
23. Tcheng JE, Talley JD, Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 2001; 88: 1097-102
24. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94
25. Gilchrist I, Conor S. Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher dose, double bolus eptifibatide in percutaneous coronary interventions. Circulation 2001; 104: 406-11
26. IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. IMPACT-II. Lancet 1997; 349: 1422-8
27. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. IMPACT Investigators. Circulation 1995; 91: 2151-7
28. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol 1997; 80 Suppl. 4A: 21B-8B
29. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation: a randomized, placebo-controlled trial. Lancet 2000; 356: 2037-44
30. O'Shea JC, Hafley G, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2001; 285: 2468-73
31. O'Shea JC, Buller CE, Cantor WJ, et al. Long term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287: 618-21
32. Fintel DJ, Ledley GS. Management of patients with non-ST segment elevation acute coronary syndromes: insight from the PURSUIT trial. Clin Cardiol 2000; 23 Suppl. V: V1-V12
33. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998: 339: 436-43
34. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987; 76: 142-54
35. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
36. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention. Results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003; 41: 20-5
37. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-44
38. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359: 189-98
39. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61
40. Berdan L, Lorenz TJ, Hochman JS. Eptifibatide reduces the incidence of coronary events in patients with non-ST elevation ACS undergoing early cardiac catheterization and revascularization regardless of patient gender (abstract). J Am Coll Cardiol 2000; 35 Suppl. A (2): 343
41. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
42. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92
43. CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997: 349: 1429-35
44. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators: Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96: 1445-53
45. Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: results from the ESPRIT trial [abstract]. Circulation 2001; 104 (17): II-386
46. Morrow D, Cannon C, Rifai N, et al. Ability of minor elevations of troponin 1 and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction. Results from a randomized trial. JAMA 2001; 286: 2405-12
47. PRISM study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505
48. PRISM PLUS study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-97
49. PARAGON Investigators. International, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina. Circulation 1998; 97: 2386-95
50. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915-24